AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1796819
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (another corticosteroid of differing potency) applied for 4 weeks
Trial: 6689490
Drug: Pirenzepine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (100 mg daily for 7 days)
Trial: 6689490
Drug: Antacid (Maalox,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid (Maalox, 105 ml daily for 7 days)
Trial: 6689490
Drug: Pirenzepine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (100 mg daily for 7 days) in healthy volunteers
Trial: 31342624
Drug: Abatacept 125
RxNorm normalized name: abatacept 125 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept 125 mg
Trial: 23784898
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone (5 g/day)
Trial: 23784898
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone (10 g/day)
Trial: 23784898
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant GH (0 μg/kg/day)
Trial: 23784898
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant GH (3 μg/kg/day)
Trial: 23784898
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant GH (5 μg/kg/day)
Trial: 9496213
Drug: Soda lime
RxNorm normalized name: SODA LIME
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soda lime with 60 ml of water added (water group)
Trial: 8201800
Drug: Zopiclone (ZPC)
DrugBank: Zopiclone (DB01198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zopiclone (ZPC) 10 mg
Trial: 23907087
Drug: Rectal stimulation
RxNorm normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal stimulation and/or small volume enemas
Trial: 23907087
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (rectal stimulation/enemas)
Trial: 19118966
Drug: Mesalazine in
RxNorm normalized name: Product containing mesalazine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine in medication stratum
Trial: 17562631
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality distraction intervention during chemotherapy
Trial: 17562631
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention (control) during matched chemotherapy treatment
Trial: 26628206
Drug: Clinical Case
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical Case Management integrated with Problem-Solving Therapy (CM-PST)
Trial: 12690054
Drug: L-dopa treatment
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-dopa treatment
Trial: 12690054
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (L-dopa + STN stimulation)
Trial: 12690054
Drug: L-dopa, STN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa, STN stimulation, and combined treatment
Trial: 1736456
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch (15 +/- 3.5 mg of nicotine in 16 hours)
Trial: 1774568
Drug: Sequential compression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential compression devices (SCD)
Trial: 24529603
Drug: Multi-convergent therapy
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-convergent therapy (MCT) for 16 weeks
Trial: 22378825
Drug: Fetal ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fetal ethanol exposure (administered to dams through a liquid diet)
Trial: 20470336
Drug: Midazolam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.5 mg x kg(‐1) in 5 ml of honey)
Trial: 20470336
Drug: Midazolam-Ketamine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam-Ketamine (0.25 mg x kg(‐1) midazolam mixed with 1 mg x kg(‐1) ketamine in 5-ml honey)
Trial: 20470336
Drug: Placebo (5-ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5-ml honey alone)
Trial: 18257184
Drug: L-Dopa (Control)
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: L-Dopa (Control)
Trial: 16416346
Drug: T4 treatment
RxNorm normalized name: T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: T4 treatment for hypothyroidism
Trial: 12801161
Drug: Sertraline at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline at a dosage of 200 mg/day during the 8-week open-label extension phase.
Trial: 12801161
Drug: Sertraline at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline at a dosage of 100 mg/day during the acute phase.
Trial: 10929571
Drug: bupropion-SR 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupropion-SR 150 mg/day
Trial: 10929571
Drug: bupropion-SR 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupropion-SR 300 mg/day
Trial: 8842507
Drug: Intravenous propafenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propafenone (2 mg/kg iv over 10 minutes followed by 0.007 mg/kg/min)
Trial: 8842507
Drug: Intravenous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous placebo (0.9% saline solution)
Trial: 7484039
Drug: esmolol 2
RxNorm normalized name: esmolol 20 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: esmolol 2 mg.kg‐1
Trial: 788993
Drug: Aspirin 1200
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 1200 mg
Trial: 12799117
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil formulation dentifrice
Trial: 1735697
Drug: AK-2123 (3-nitro-1,2,4-triazole)
RxNorm normalized name: 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AK-2123 (3-nitro-1,2,4-triazole) intratumoral injection at 1% and 2%
Trial: 1735697
Drug: AK-2123 (3-nitro-1,2,4-triazole)
RxNorm normalized name: 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AK-2123 (3-nitro-1,2,4-triazole) intratumoral injection
Trial: 6365350
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg orally every 4 hr for 14 days)
Trial: 30103622
Drug: Patiromer (8.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patiromer (8.4 g/d to start, adjusted to maintain serum potassium of 3.8 to 5.0 mEq/L)
Trial: 20210620
Drug: gel jacket
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gel jacket
Trial: 18538692
Drug: Anti-NB treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-NB treatment
Trial: 16006454
Drug: 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day acarbose
Trial: 10049281
Drug: Stavudine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stavudine (40 mg twice daily) in combination with one to three other drugs for opportunistic infections
Trial: 10049281
Drug: Stavudine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stavudine (40 mg twice daily)
Trial: 8657058
Drug: Doxycycline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (200 mg on the first day, then 100 mg daily for 13 days)
Trial: 8657058
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (same parodontal therapy without doxycycline)
Trial: 348309
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (CY), 60 mg/kg iv, given on Days 1 and 2
Trial: 348309
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (CY), 60 mg/kg iv, given on Days 1 and 8
Trial: 348309
Drug: COMB (CY,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMB (CY, 800 mg/m2; vincristine [Oncovin], 1.4 mg/m2; methotrexate, 20 mg/m2; and BCNU, 60 mg/m2)
Trial: 11107508
Drug: Intracoronary administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary administration of dipyridamole (0.5 mg/kg body weight)
Trial: 9236429
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of Ang II
Trial: 29485790
Drug: Paracetamol administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol administered through patient-controlled analgesia (PCA) pump
Trial: 29485790
Drug: Paracetamol administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol administered intermittently
Trial: 25344090
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg AA
Trial: 25344090
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg AA
Trial: 25344090
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg AA
Trial: 25344090
Drug: 1 hour
RxNorm normalized name: Product containing precisely estradiol 312.5 nanogram/1 hour prolonged-release vaginal ring (clinical drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 hour premeal 1000 mg AA
Trial: 25344090
Drug: 2 hours
RxNorm normalized name: PATCH, TRANSDERMAL 72 HOURS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 hours postmeal 1000 mg AA
Trial: 25344090
Drug: 4 hours
RxNorm normalized name: PATCH, TRANSDERMAL 24 HOURS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 hours apart meals 1000 mg AA
Trial: 19144392
Drug: NovaSil clay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NovaSil clay (high dose)
Trial: 19144392
Drug: NovaSil clay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NovaSil clay (low dose)
Trial: 14709460
Drug: Continuous three‐in‐one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous three‐in‐one femoral nerve block (FEM) with 30 mL ropivacaine 0.5% and epinephrine 1:200,000 bolus followed by an infusion of ropivacaine 0.2% at 12 mL/hr for 48 hr
Trial: 14709460
Drug: Continuous posterior
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous posterior lumbar plexus (PSOAS) block with the same bolus and infusion regimen as the FEM group
Trial: 14709460
Drug: iv patient‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv patient‐controlled morphine analgesia (PCA)
Trial: 11826911
Drug: Loratadine syrup
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loratadine syrup 5 mg or 10 mg daily for 3 weeks
Trial: 8956350
Drug: l-methadone (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-methadone (n = 13)
Trial: 29972633
Drug: Apixaban 10
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban 10 mg with Cyclosporine 100 mg
Trial: 29972633
Drug: Apixaban 10
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban 10 mg with Tacrolimus 5 mg
Trial: 26760084
Drug: Intensified treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified treatment (higher-dose rifampin 15 mg/kg/day and levofloxacin 20 mg/kg/day for the first 8 weeks)
Trial: 26760084
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen (10 mg rifampin/kg/day for 9 months)
Trial: 22554203
Drug: Artemisinin-naphthoquine (AN)
RxNorm normalized name: naphthoquine
DrugBank: Naphthoquine (DB16249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin-naphthoquine (AN) - single dose of four tablets on day 0
Trial: 22554203
Drug: Dihydroartemisinin-piperaquine (DHP)
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine (DHP) - three to four tablets daily for three days
Trial: 19088171
Drug: Vandetanib 100
RxNorm normalized name: vandetanib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 100 mg + pemetrexed (500 mg/m2 i.v. every 21 days)
Trial: 19088171
Drug: Vandetanib 300
RxNorm normalized name: vandetanib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 300 mg + pemetrexed (500 mg/m2 i.v. every 21 days)
Trial: 19088171
Drug: Vandetanib 100
RxNorm normalized name: vandetanib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 100 mg + pemetrexed
Trial: 19088171
Drug: Vandetanib 300
RxNorm normalized name: vandetanib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 300 mg + pemetrexed
Trial: 16449845
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Nicotinic acid and Bezafibrate
Trial: 12133363
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (NO) in group B(1), n = 20
Trial: 9818786
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg picotamide daily
Trial: 6107116
Drug: Clobazam 10
RxNorm normalized name: cloBAZam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam 10 mg three times daily
Trial: 35211
Drug: Chlordiazepoxide 10
RxNorm normalized name: chlordiazepoxide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlordiazepoxide 10 mg three times daily
Trial: 28403662
Drug: Soluble intercellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble intercellular adhesion molecule 1 (sICAM‐1)
Trial: 28403662
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CPIS and SAA
Trial: 27632342
Drug: Hydrogel spacer
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogel spacer injection before RT
Trial: 26402319
Drug: Combination sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination sedation (repeated bolus doses of fentanyl with propofol infusion)
Trial: 26402319
Drug: Conventional sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional sedation (initial bolus of meperidine with propofol infusion)
Trial: 26402319
Drug: Combination sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination sedation
Trial: 15497670
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (30 mg pioglitazone hydrochloride)
Trial: 15497670
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (30 mg pioglitazone hydrochloride)
Trial: 15497670
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation and Reference formulation
Trial: 9466097
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections pre- and intra-operatively (Group A)
Trial: 9466097
Drug: Placebo pre-operatively
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo pre-operatively and ketorolac 30 mg intra-operatively (Group B)
Trial: 9466097
Drug: Ketorolac 10
RxNorm normalized name: ketorolac 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 10 mg pre-operatively and ketorolac 20 mg intra-operatively (Group C)
Trial: 9466097
Drug: Ketorolac 30
RxNorm normalized name: ketorolac 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 30 mg pre-operatively and placebo intra-operatively (Group D)
Trial: 7887164
Drug: Povidone-iodine solution
RxNorm normalized name: POVIDONE-IODINE 1 g in 100 mL TOPICAL LIQUID [Loris Povidone-Iodine Solution]
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine solution 5% applied prior to preoperative wash of the fornices with normal saline.
Trial: 2895319
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (59 patients)
Trial: 12366728
Drug: Topiramate 200
RxNorm normalized name: topiramate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate 200 mg
Trial: 25433970
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with 1:100,000 epinephrine administered by male operators to female subjects
Trial: 25433970
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with 1:100,000 epinephrine administered by female operators to male subjects
Trial: 25433970
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with 1:100,000 epinephrine administered by male operators to male subjects
Trial: 25433970
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with 1:100,000 epinephrine administered by female operators to female subjects
Trial: 18628449
Drug: Multi-arm experimental
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-arm experimental treatments
Trial: 12973834
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) - 2 cycles
Trial: 12973834
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) - 1 cycle
Trial: 8710750
Drug: Cetylpyridinium chloride
RxNorm normalized name: Cetylpyridinium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetylpyridinium chloride in candy based lozenges
Trial: 8710750
Drug: Aqueous solutions
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous solutions of the lozenges
Trial: 1711614
Drug: Bendrofluazide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide (10 mg/day)
Trial: 6354023
Drug: Chlorpheniramine maleate
RxNorm normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine maleate (18 mg nebulized)
Trial: 6354023
Drug: Atropine sulphate
RxNorm normalized name: Atropine sulphate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulphate (3 mg nebulized)
Trial: 6354023
Drug: Atropine sulphate
RxNorm normalized name: Atropine sulphate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulphate (18 mg nebulized)
Trial: 27773851
Drug: Intradermal allergen
RxNorm normalized name: catfish allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal allergen injections (7 ng of Phl p 5 major allergen)
Trial: 27513252
Drug: Propofol (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.75 mg/kg iv)
Trial: 24290345
Drug: Oligofructose/inulin 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oligofructose/inulin 7 g/d
Trial: 22122999
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg aspirin only once daily
Trial: 22122999
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg aspirin + 20 mg famotidine twice daily
Trial: 22122999
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg rabeprazole once daily
Trial: 17395869
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (balloon angioplasty or stenting)
Trial: 15802975
Drug: High ddI
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High ddI doses or taking a third NA
Trial: 11867504
Drug: N-acetyl-L-cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetyl-L-cysteine (NAC) 2 x 600 mg oral tablets
Trial: 10464891
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide 800 micrograms per day
Trial: 8557242
Drug: Insulin analogue
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin analogue (B28Asp)
Trial: 31006728
Drug: Ethyl icosapentate
RxNorm normalized name: Ethyl icosapentate
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ethyl icosapentate (EPA) 1.8 g t.i.d.
Trial: 31006728
Drug: EPA+DHA 2
RxNorm normalized name: eicosapentaenoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA+DHA 2 g s.i.d.
Trial: 26281201
Drug: 0.1% tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% tacrolimus ointment and azathioprine 2 mg/kg/day
Trial: 26281201
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with azathioprine 2 mg/kg/day, hormone ointment 1 mg/day, and metronidazole suppositories 250 mg/day